[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

AI In Oncology Market Size, Share & Trends Analysis Report By Component (Software Solutions, Hardware, Services), By Cancer Type, By Treatment Type, By Region, And Segment Forecasts, 2022 - 2030

October 2022 | 80 pages | ID: A942A9DB395DEN
Grand View Research, Inc.

US$ 5,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 4 Business Days

AI In Oncology Market Growth & Trends

The global AI in oncology market size is expected to reach USD 9.6 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 35.6 % from 2022 - 2030. The use of Artificial intelligence (AI) technologies helps clinicians in the early detection of cancer and plan treatment procedures according to the condition of the patient. The growth of the market is attributed to the rising number of patients diagnosed with cancer. According to data published by the American Cancer Society as of 2021, more than 1.9 million people are estimated to be diagnosed with cancer in the U.S.

Moreover, the increasing adoption of AI for diagnostic and therapeutic applications and the rising adoption of digitalization in hospitals and research facilities is anticipated to further boost the adoption of these technologies during the forecast period. The use of AI/ML can be trained to analyze the patient's health information which helps clinicians in quick and accurate diagnosis of cancer.

Increasing healthcare expenditure by governments across the world is projected to significantly boost the growth of the market. For instance, healthcare spending by the Australian Government increased from USD 94.5 billion in 2020-21 to USD 98.3 billion in 2021-22. This increase in healthcare expenditure is anticipated to increase the adoption of digital technologies in the hospital and healthcare facilities in order to provide a better patient outcome. Furthermore, the increasing number of startups that provide innovative solutions is supporting market growth. For instance, X-ZELL a Singapore-based startup specializes in early cancer detection by integrating artificial intelligence with next-generation single-cell detection technology to detect cancer at the earliest stages accurately, non-invasively and affordably.

Partnerships and collaborations between public and private players is anticipated to boost the adoption of the services. For instance, In August 2021, Verily Lifesciences, a subsidiary of Alphabet Inc. announced a partnership with Jerusalem Hospital in Israel wherein the company aims to use AI to manage and treat diseases. The initiative will focus on using AI to detect and treat colorectal cancer which kills approximately 900,000 patients every year.

AI In Oncology Market Report Highlights
  • In 2021, the software solutions segment held a revenue share of 43.3% due to the increased adoption of software to provide better clinical outcomes and the availability of software for various applications
  • In 2021, the others segment which included Leukemia, skin cancer, and stomach cancer among others contributed a share of 34.0%. Increasing incorporation of AI for diagnosis and treatment of these cancers combined with increasing prevalence among the population are some of the key factors that contributed to the growth of the segment
  • In 2021, the chemotherapy segment held the largest revenue share of 36.2% due to a higher number of patients undergoing chemotherapy to treat cancer
  • In 2021, North America contributed 58.4% share due to the availability of favorable government initiatives and digital infrastructure to provide digital solutions to the patients
CHAPTER 1. METHODOLOGY AND SCOPE

1.1. Market Segmentation and Scope
1.2. Market Definition
1.3. Research Methodology
  1.3.1. Information Procurement
    1.3.1.1. Purchased database
    1.3.1.2. GVR’s internal database
  1.3.2. Primary Research
1.4. Research Scope and Assumptions
1.5. List to Data Sources

CHAPTER 2. EXECUTIVE SUMMARY

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
2.4. AI in Oncology Market

CHAPTER 3. AI IN ONCOLOGY MARKET VARIABLES, TRENDS, & SCOPE

3.1. Penetration and Growth Prospect Mapping
3.2. Market Dynamics
3.3. AI in Oncology Market Analysis Tools
  3.3.1. Industry Analysis - Porter’s
    3.3.1.1. Bargaining power of the suppliers
    3.3.1.2. Bargaining power of the buyers
    3.3.1.3. Threats of substitution
    3.3.1.4. Threats from new entrants
    3.3.1.5. Competitive rivalry
  3.3.2. PESTEL Analysis
    3.3.2.1. Political landscape
    3.3.2.2. Economic and Social landscape
    3.3.2.3. Technological landscape
  3.3.3. Impact of COVID-19 on the market

CHAPTER 4. CHAPTER 5 AI IN ONCOLOGY MARKET: COMPONENT ESTIMATES & TREND ANALYSIS

4.1. Definitions & Scope
4.2. AI in Oncology Market: Component Movement Analysis, 2021 & 2030 (USD Million)
4.3. Software Solutions
  4.3.1. Software Solutions market estimates and forecasts, 2016 - 2030 (USD Million)
4.4. Hardware
  4.4.1. Hardware market estimates and forecasts, 2016 - 2030 (USD Million)
4.5. Services
  4.5.1. Services market estimates and forecasts, 2016 - 2030 (USD Million)

CHAPTER 5. AI IN ONCOLOGY MARKET: CANCER TYPE ESTIMATES & TREND ANALYSIS

5.1. Definitions and Scope
5.2. AI in Oncology Market: Cancer Type Movement Analysis, 2021 & 2030 (USD Million)
5.3. Breast Cancer
  5.3.1. Breast Cancer market estimates and forecasts, 2016 - 2030 (USD Million)
5.4. Lung Cancer
  5.4.1. Lung Cancer market estimates and forecasts, 2016 - 2030 (USD Million)
5.5. Prostate Cancer
  5.5.1. Prostate Cancer market estimates and forecasts, 2016 - 2030 (USD Million)
5.6. Colorectal Cancer
  5.6.1. Colorectal Cancer market estimates and forecasts, 2016 - 2030 (USD Million)
5.7. Brain Tumor
  5.7.1. Brain Tumor market estimates and forecasts, 2016 - 2030 (USD Million)
5.8. Others
  5.8.1. Others market estimates and forecasts, 2016 - 2030 (USD Million)

CHAPTER 6. AI IN ONCOLOGY MARKET: TREATMENT TYPE ESTIMATES & TREND ANALYSIS

6.1. Definitions & Scope
6.2. AI in Oncology Market: Treatment Type Movement Analysis, 2021 & 2030 (USD Million)
6.3. Chemotherapy
  6.3.1. Chemotherapy market estimates and forecasts, 2016 - 2030 (USD Million)
6.4. Radiotherapy
  6.4.1. Radiotherapy market estimates and forecasts, 2016 - 2030 (USD Million)
6.5. Immunotherapy
  6.5.1. Immunotherapy market estimates and forecasts, 2016 - 2030 (USD Million)
6.6. Others
  6.6.1. Others market estimates and forecasts, 2016 - 2030 (USD Million)

CHAPTER 7. AI IN ONCOLOGY MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

7.1. Regional Market Snapshot
7.2. AI in Oncology Market: Regional Movement Analysis
7.3. North America
  7.3.1. North America market estimates and forecasts, by component 2016 - 2030 (USD Million)
  7.3.2. North America market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
  7.3.3. North America market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.3.4. U.S.
    7.3.4.1. U.S. market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.3.4.2. U.S. market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.3.4.3. U.S. market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.3.5. Canada
    7.3.5.1. Canada market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.3.5.2. Canada market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.3.5.3. Canada market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.4. Europe
  7.4.1. Europe market estimates and forecasts, by component 2016 - 2030 (USD Million)
  7.4.2. Europe market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
  7.4.3. Europe market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.4.4. Germany
    7.4.4.1. Germany market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.4.4.2. Germany market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.4.4.3. Germany market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.4.5. U.K.
    7.4.5.1. U.K. market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.4.5.2. U.K. market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.4.5.3. U.K. market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.4.6. France
    7.4.6.1. France market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.4.6.2. France market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.4.6.3. France market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.4.7. Italy
    7.4.7.1. Italy market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.4.7.2. Italy market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.4.7.3. Italy market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.4.8. Spain
    7.4.8.1. Spain market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.4.8.2. Spain market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.4.8.3. Spain market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.4.9. Russia
    7.4.9.1. Russia market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.4.9.2. Russia market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.4.9.3. Russia market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.5. Asia Pacific
  7.5.1. Asia Pacific market estimates and forecasts, by component 2016 - 2030 (USD Million)
  7.5.2. Asia Pacific market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
  7.5.3. Asia Pacific market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.5.4. Japan
    7.5.4.1. Japan market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.5.4.2. Japan market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.5.4.3. Japan market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.5.5. China
    7.5.5.1. China market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.5.5.2. China market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.5.5.3. China market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.5.6. India
    7.5.6.1. India market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.5.6.2. India market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.5.6.3. India market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.5.7. Australia
    7.5.7.1. Australia market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.5.7.2. Australia market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.5.7.3. Australia market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.5.8. South Korea
    7.5.8.1. South Korea market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.5.8.2. South Korea market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.5.8.3. South Korea market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.6. Latin America
  7.6.1. Latin America market estimates and forecasts, by component 2016 - 2030 (USD Million)
  7.6.2. Latin America market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
  7.6.3. Latin America market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.6.4. Brazil
    7.6.4.1. Brazil market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.6.4.2. Brazil market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.6.4.3. Brazil market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.6.5. Mexico
    7.6.5.1. Mexico market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.6.5.2. Mexico market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.6.5.3. Mexico market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.6.6. Argentina
    7.6.6.1. Argentina market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.6.6.2. Argentina market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.6.6.3. Argentina market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
7.7. MEA
  7.7.1. MEA market estimates and forecasts, by component 2016 - 2030 (USD Million)
  7.7.2. MEA market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
  7.7.3. MEA market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.7.4. South Africa
    7.7.4.1. South Africa market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.7.4.2. South Africa market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.7.4.3. South Africa market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.7.5. Saudi Arabia
    7.7.5.1. Saudi Arabia market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.7.5.2. Saudi Arabia market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.7.5.3. Saudi Arabia market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)
  7.7.6. UAE
    7.7.6.1. UAE market estimates and forecasts, by component 2016 - 2030 (USD Million)
    7.7.6.2. UAE market estimates and forecasts, by cancer type 2016 - 2030 (USD Million)
    7.7.6.3. UAE market estimates and forecasts, by treatment type 2016 - 2030 (USD Million)

CHAPTER 8. AI IN ONCOLOGY MARKET - COMPETITIVE ANALYSIS

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Competition Categorization
8.3. Company Market Position Analysis

CHAPTER 9. COMPETITIVE LANDSCAPE: COMPANY PROFILES

9.1. Azra AI
  9.1.1. Company overview
  9.1.2. Financial performance
  9.1.3. Product benchmarking
  9.1.4. Strategic initiatives
9.2. IBM
  9.2.1. Company overview
  9.2.2. Financial performance
  9.2.3. Product benchmarking
  9.2.4. Strategic initiatives
9.3. Siemens Healthineers
  9.3.1. Company overview
  9.3.2. Financial performance
  9.3.3. Product benchmarking
  9.3.4. Strategic initiatives
9.4. Intel
  9.4.1. Company overview
  9.4.2. Financial performance
  9.4.3. Product benchmarking
  9.4.4. Strategic initiatives
9.5. GE Healthcare
  9.5.1. Company overview
  9.5.2. Financial performance
  9.5.3. Product benchmarking
  9.5.4. Strategic initiatives
9.6. NVIDIA
  9.6.1. Company overview
  9.6.2. Financial performance
  9.6.3. Product benchmarking
  9.6.4. Strategic initiatives
9.7. Digital Diagnostics Inc.
  9.7.1. Company overview
  9.7.2. Financial performance
  9.7.3. Product benchmarking
  9.7.4. Strategic initiatives
9.8. Concert.AI
  9.8.1. Company overview
  9.8.2. Financial performance
  9.8.3. Product benchmarking
  9.8.4. Strategic initiatives
9.9. Median Technologies
  9.9.1. Company overview
  9.9.2. Financial performance
  9.9.3. Product benchmarking
  9.9.4. Strategic initiatives
9.10. Path AI
  9.10.1. Company overview
  9.10.2. Financial performance
  9.10.3. Product benchmarking
  9.10.4. Strategic initiatives
LIST OF TABLES

Table 1 Factors used in segment share estimation
Table 2 List of secondary data sources
Table 3 Primary interview details, by source
Table 4 Primary interview details, by region
Table 5 North America market estimates and forecasts, by country, 2016 - 2030 (USD Million)
Table 6 North America market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 7 North America market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 8 North America market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 9 U.S. market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 10 U.S. market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 11 U.S. market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 12 Canada market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 13 Canada market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 14 Canada market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 15 Europe market estimates and forecasts, by country, 2016 - 2030 (USD Million)
Table 16 Europe market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 17 Europe market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 18 Europe market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 19 Germany market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 20 Germany market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 21 Germany market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 22 U.K. market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 23 U.K. market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 24 U.K. market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 25 France market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 26 France market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 27 Italy market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 28 Italy market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 29 Italy market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 30 Spain market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 31 Spain market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 32 Spain market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 33 Russia market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 34 Russia market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 35 Russia market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 36 Asia Pacific market estimates and forecasts, by country, 2016 - 2030 (USD Million)
Table 37 Asia Pacific market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 38 Asia Pacific market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 39 Asia Pacific market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 40 Japan market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 41 Japan market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 42 Japan market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 43 China market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 44 China market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 45 China market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 46 India market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 47 India market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 48 India market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 49 Australia market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 50 Australia market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 51 Australia market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 52 Singapore market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 53 Singapore market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 54 Singapore market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 55 South Korea market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 56 South Korea market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 57 South Korea market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 58 Latin America market estimates and forecasts, by country, 2016 - 2030 (USD Million)
Table 59 Latin America market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 60 Latin America market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 61 Latin America market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 62 Brazil market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 63 Brazil market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 64 Brazil market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 65 Mexico market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 66 Mexico market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 67 Mexico market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 68 Argentina market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 69 Argentina market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 70 Argentina market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 71 MEA market estimates and forecasts, by country, 2016 - 2030 (USD Million)
Table 72 MEA market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 73 MEA market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 74 MEA market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 75 South Africa market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 76 South Africa market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 77 South Africa market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 78 Saudi Arabia market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 79 Saudi Arabia market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 80 Saudi Arabia market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
Table 81 UAE market estimates and forecasts, by component, 2016 - 2030 (USD Million)
Table 82 UAE market estimates and forecasts, by cancer type, 2016 - 2030 (USD Million)
Table 83 UAE market estimates and forecasts, by treatment type, 2016 - 2030 (USD Million)
LIST OF FIGURES

Fig. 1 Market research process
Fig. 2 Data Triangulation Techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market Snapshot
Fig. 9 AI in Oncology Market variables, trends & scope
Fig. 10 Penetration & Growth Prospect Mapping
Fig. 11 Technology Timeline (Transition / various technology adoption past & future predictions)
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Company/Competition Categorization
Fig. 15 Company market position analysis
Fig. 16 Component market share analysis, 2021 & 2030
Fig. 17 Segment Dashboard
Fig. 18 Software Solutions market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 19 Hardware market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 20 Services market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 21 Cancer type market share analysis, 2021 & 2030
Fig. 22 Segment Dashboard
Fig. 23 Breast Cancer market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 24 Lung Cancer market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 25 Prostate Cancer market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 26 Colorectal Cancer market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 27 Brain Tumor market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 28 Others market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 29 Treatment type market share analysis, 2021 & 2030
Fig. 30 Segment Dashboard
Fig. 31 Chemotherapy market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 32 Radiotherapy market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 33 Immunotherapy market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 34 Others market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 35 Regional market place: Key takeaways
Fig. 36 AI in Oncology Market: Regional outlook, 2021 & 2030 (USD Million)
Fig. 37 North America market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 38 U.S. market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 39 Canada market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 40 Europe market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 41 Germany market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 42 U.K. market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 43 France market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 44 Italy market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 45 Spain market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 46 Russia market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 47 Asia Pacific market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 48 Japan market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 49 China market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 50 India market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 51 Australia market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 52 South Korea market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 53 Latin America market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 54 Brazil market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 55 Mexico market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 56 Argentina market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 57 MEA market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 58 South Africa market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 59 Saudi Arabia market revenue estimates and forecasts, 2016 - 2030 (USD Million)
Fig. 60 UAE market revenue estimates and forecasts, 2016 - 2030 (USD Million)


More Publications